Contact Information
Meyer Kattan, MD
Lazina Lorick
(212) 305-4930
(212) 342-5756

1. Clinical Research


Asthma is a major public health problem that disproportionately affects children living inner-cities. Our research has looked at environmental and psychosocial factors affecting outcome as well as issues of health care delivery.

  • Clinical Trial of Chinese Herbal Therapy in Asthma Patients
  • Inner-City Asthma Consortium: Immunologic approaches to reduce asthma. To understand allergic mechanisms in the development of asthma and to develop immune-mediated interventions. Meyer Kattan, MD; Carin Lamm, MD (NIH-NIAID N01 A1 90052)
  • Comparative effectiveness of environmental intervention and standard care in ability to reduce pharmaceuticals in asthma. Meyer Kattan, MD; Emily DiMango, MD; Beverley Sheares, MD, MS (NIH 1 RO1 HS019384-01)

Cystic Fibrosis

The Cystic Fibrosis Center is part of the Cystic Fibrosis Foundation Therapeutics Development Network (TDN) which participates in clinical trials of novel therapies for CF. The Center is also involved in investigator initiated studies of the microbiologic complications of CF with a specific interest in the implications of MRSA and CF and the respiratory microbiology of infants with CF identified by newborn screening.


  • Racial and Ethnic Differences in Childhood Sleep Behaviors. Beverley Sheares, MD; Carin Lamm, MD (NIH-NHLBI 5 RO1 HL092856-03)

Neuromuscular Disorders

The Division of Pulmonology participates in multidisciplinary clinical trials supported by the Motor Neuron Center.

  • Natural History Study of Spinal Muscular Atrophy; Andre Constantinescu, MD, PhD (PNCR consortium)

Sickle Cell Anemia

Phase 2 Study of Vitamin D for Treatment of Respiratory Complications in Sickle Cell Disease Co-investigator: Meyer Kattan, MD (FDA)

2. Laboratory and Translational Research

Hormonal regulation of lung function and its implications to obesity-associated asthma

Dr. Arteaga-Solis investigates the role of adipocyte-derived hormones and their contribution to airway physiology and pathology. His recent studies demonstrated that leptin regulates airway diameter through a novel neuronal pathway that is altered in obesity. These studies dissociated body mass and inflammation from the airflow limitations that characterize this disease. To expand on his work on leptin, he is now studying the function of other adipocyte-derived hormones in lung physiology and how they affect allergen- and obesity-induced asthma.

Anticholinergic agents as a treatment for obesity-associated asthma

Dr. Arteaga-Solis recent identification of increased parasympathetic activity in genetically and diet-induced obese mice implied that anticholinergic agents may be beneficial for the treatment of obesity-associated asthma. In fact, treatment of animal models of obesity with anticholinergic agents alleviated their disease. These findings let to his collaboration with the Inner City Asthma Consortium to test if ipratropium bromide, a short acting anticholinergic agent, has a preferential benefit in obese asthmatic children as compared to those of normal weight.